

Discussion topics on “Access to medicines” (session 3.2)

- Role of patients and HCPs at the intersection of regulatory review and Health Technology Assessment, across the life cycle (engagement)
- Experiences and challenges by patients and HCPs in terms of access to medicines in health care systems and identification of topics where EMA/HTA cooperation could help



Focus on accessibility issues from the perspective of commercialization / downstream decision making (i.e. not supply disruption / shortages).

The topic is multi-dimensional and complex: Questions to kick-start the discussion

- What is the level of **awareness** in your communities on the decision-making ecosystem and – if needed - what would be means to strengthen this?
- Where could you see an enhanced engagement in the context of **evidence generation** to support decision-making?
- How could we **support your organisations** in your activities related to access discussions (e.g. workshops/conferences you organise)?
- Would you see the potential / need for a more **dedicated follow-up** discussion / surveys on these topics?

Aim to identify a few concrete asks / proposals for actionable items that are meaningful and can be progressed.